Conference Coverage

High RA biologic drug levels linked with more infections

Publish date: June 29, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Jani M et al. EULAR 2018 Congress, Abstract OP0229.

Pages

Recommended Reading

Malignancy risk of tocilizumab and TNF inhibitors found similar
MDedge Internal Medicine
Functional disability prevails despite rheumatoid arthritis treatment
MDedge Internal Medicine
NIH cans study that relied on millions in funding from alcohol companies
MDedge Internal Medicine
TNF inhibitor linked to one-third drop in total mortality
MDedge Internal Medicine
Serum troponin predicts cardiovascular death in early arthritis
MDedge Internal Medicine
Severe OA sparks depression, surgery “ameliorates” depression in RA
MDedge Internal Medicine
Heart failure confers poor prognosis in rheumatoid arthritis
MDedge Internal Medicine
IMAGINE-RA: No need for MRI with treat-to-target strategy
MDedge Internal Medicine
Glucocorticosteroid use raises sarcopenia risk in RA
MDedge Internal Medicine
EULAR recommendations on steroids: ‘As necessary, but as little as possible’
MDedge Internal Medicine

Related Articles